Appeal No. 1997-2184
Application 08/278,441
or a non-interfering substituent having a total of 1
to 3 atoms other than hydrogen;
R and R are independently selected from hydrogen, a6 7
non-interfering substituent, or the group,
-(L )-(acidic-group); wherein -(L )-, is an acida a
linker having an acid linker length of 1 to 10;
provided, that at least one of R and R must be the6 7
group,
-(La)-(acidic group); and
R and R are each independently selected from4 5
hydrogen, non-interfering substituent, carbocyclic
radical, carbocyclic radical substituted with
non-interfering substituents, heterocyclic radical,
and heterocyclic radical substituted with
non-interfering substituents.
Claim 11. A pharmaceutical formulation comprising
the indene-1-acetamide as claimed in Claim 1
together with a pharmaceutically acceptable carrier
or diluent therefor.
Claim 14. A method of treating a mammal to alleviate
the pathological effects of septic shock, adult
respiratory distress syndrome, pancreatitis, trauma,
bronchial asthma, allergic rhinitis, and rheumatoid
arthritis; wherein the method comprises
administration to said mammal of at least one
indene-1-acetamide as claimed in Claim 1 in an
amount sufficient to inhibit sPLA mediated release
2
of fatty acid and to thereby inhibit or prevent the
arachidonic acid cascade and its deleterious
products.
OPINION
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007